Estrella Immunopharma, Inc. 8-K

What Happened

• Estrella Immunopharma, Inc. filed an 8-K on June 30, 2026 reporting the results of its Combined 2025/2026 Annual Meeting held virtually on June 29, 2026. The record date was May 20, 2026.
• Stockholders ratified the appointment of Macias Gini & O’Connell LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. A quorum was present.

Key Details

• Record date: May 20, 2026; Meeting: June 29, 2026 (virtual-only).
• Shares outstanding: 43,034,228; Shares present or represented: 30,351,608 (≈70.5%).
• Vote on auditor ratification: For 30,351,203; Against 400; Abstain 5; Broker non‑votes 0.
• Proxy statement describing the proposal was filed on Schedule 14A on May 27, 2026.

Why It Matters

• Ratifying the independent auditor is a routine but important governance action that confirms who will audit the company’s financial statements for the coming fiscal year. The vote was overwhelmingly in favor with strong shareholder participation (~70.5%), indicating broad support for the appointment. No management or financial changes were reported in this filing.